03/18/2026
Webinar #1: Navigating Bioanalytical Challenges: from Small Molecules to Complex Peptides
Developing robust LC-MS/MS methods for small molecules and peptides can present significant challenges.
Low molecular weight compounds often exhibit poor ionization, losses due to volatility during sample preparation, and interference from endogenous isobaric compounds.
Peptides add another layer of complexity, which is even more pronounced when working with basic peptides or GLP-1 analogues. In comparison to more standard peptides, basic peptides suffer from poorer chromatographic retention and increased signal dilution across multiple charge states, while GLP-1 analogues, like Semaglutide and Liraglutide, undergo higher non-specific binding and persistent carryover due to their hydrophobic fatty acid chain.
These challenges can delay timelines and compromise data quality. Understanding when standard approaches fall short and what alternatives exist, is essential for efficient method development.
What You Will Learn
In this 30-minute on-demand webinar, you will learn practical troubleshooting strategies for different types of analytical challenges.
Our team covers several topics, from how to manage volatility and cross-contamination during sample preparation for low molecular weight compounds, to when to consider alternative ionization sources like APCI over ESI, or how perfluorinated acids can significantly improve retention, recovery and charge state distribution for basic peptides with poor chromatographic behavior.
We also discuss strategies for reducing carryover and non-specific binding in GLP-1 analogues like Semaglutide and Liraglutide, as well as practical approaches to improve peptide recovery and maintain sensitivity when working with these highly hydrophobic peptides.
Each of the strategies is illustrated with real case studies from our laboratory.
Who Is This For?
This webinar is designed for bioanalytical scientists, LC-MS/MS analytical chemists, preclinical and clinical project managers, R&D managers, and scientific leaders involved in bioanalytical outsourcing decisions.
Whether you are troubleshooting an existing method or developing a new one, you will gain practical insights that can be applied directly to your work.
Meet the Speakers
Robert Fontarnau | Moderator
Business Development Director
Jordi Ortuño | Speaker
Scientific Director - Small Molecule Bioanalysis
Albert Barroso, PhD | Speaker
Deputy Scientific Director - Small Molecule Bioanalysis
Our speakers bring decades of combined experience in LC-MS/MS bioanalysis, supporting pharmaceutical and biotech clients worldwide from preclinical through clinical Phase I–III programs.
Register Below to Watch the Webinar
MORE NEWS
ADA for a small recombinant protein: development and troubleshooting
ADA assay development is technically complex and often requires iterative optimisation to overcome challenges such as drug interference, matrix effects and non-specific binding. The aim of this poster, is to present the troubleshooting process followed during the development of an assay for the detection of ADA against a recombinant protein of 24kDa.
Challenges in the development of a method for the detection of Free Testosterone
In the present study, we aim to optimize a competitive enzyme-linked immunosorbent assay (ELISA) for the measurement of free testosterone within a regulated pharmacokinetic (PK) framework, with the objective of achieving a sensitivity in the range of 0.2–0.6 pg/mL. This poster presents key challenges encountered during method development and validation, and discusses the strategies implemented to overcome them.
Anapharm Bioanalytics GLP Certificate Renewal
Barcelona, July 2026– Anapharm Bioanalytics is pleased to announce the successful renewal of its Good Laboratory Practice (GLP) certification following the latest inspection conducted by local authority, Generalitat de Catalunya, in June 2026.
Anapharm has operated under GLP compliance since 2003 and the renewed certificate is valid until June 2028. The recent on-site inspection concluded with no observations and no findings, an outstanding result that reflects the robustness of the company’s quality system.